Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PR Newswire2021-02-11

LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

123321Alex
2021-02-16
123321Alex
Ya
DaveNg5144
2021-02-16
DaveNg5144
Ok
Richkai
2021-02-16
Richkai
Wow
Derekng
2021-02-16
Derekng
Oh
Kles5537
2021-02-16
Kles5537
Comment for coins pls
- Derekng:
  Thanks
Nujue
2021-02-15
Nujue
Help like pls thank you!
- schipperde:
  pls help like n comment too

发表看法

115

314

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2110041062?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-02-11 13:24","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2110041062","market":"us","top_or_hot":-1,"title":"Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","media":"PR Newswire","content":"<div>\n<p>LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...</p>\n\n<a href=\"https://finance.yahoo.com/news/pulmatrix-announces-40-million-registered-052400935.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-11 13:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pulmatrix-announces-40-million-registered-052400935.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...</p>\n\n<a href=\"https://finance.yahoo.com/news/pulmatrix-announces-40-million-registered-052400935.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PULM","symbol_name":"Pulmatrix, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/pulmatrix-announces-40-million-registered-052400935.html","article_id":"2110041062","we_media_id":null,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/pulmatrix-announces-40-million-registered-052400935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2110041062","pubTimestamp":1613021040,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage bio","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PULM":"Pulmatrix, Inc."},"translate_title":"Pulmatrix宣布4000万美元注册直接发行，根据纳斯达克规则在市场定价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NQmain":0.9,"PULM":0.9},"content_text":"LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of 20,000,000 shares of the Company's common stock, at a purchase price of $2.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 16, 2021, subject to the satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.The gross proceeds to Pulmatrix from this offering are expected to be $40,000,000, before deducting the placement agent's fees and other offering expenses. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.The shares of common stock (are being offered by Pulmatrix pursuant to a \"shelf\" registration statement on Form S-3 (File No. 333-230225) previously filed with the Securities and Exchange Commission (the \"SEC\") on March 12, 2019 and declared effective by the SEC on March 15, 2019. The offering of the securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the shares of common stock being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at placements@hcwco.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About PulmatrixPulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":382824322,"gmtCreate":1613433159866,"gmtModify":1634553720671,"author":{"id":"3571791273839540","authorId":"3571791273839540","name":"123321Alex","avatar":"https://static.tigerbbs.com/807b76e84e44c6640b1aaa50fcb19a44","vip":1,"crmLevel":8,"crmLevelSwitch":0},"htmlText":"Ya","listText":"Ya","text":"Ya","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382824322","repostId":2110041062,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":382886223,"gmtCreate":1613425883262,"gmtModify":1634553736155,"author":{"id":"3563596700956479","authorId":"3563596700956479","name":"DaveNg5144","avatar":"https://static.tigerbbs.com/f512a245bcf42ba3604520e2e90ef7a1","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382886223","repostId":2110041062,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":382880606,"gmtCreate":1613415856705,"gmtModify":1634553738507,"author":{"id":"3572855526693204","authorId":"3572855526693204","name":"Richkai","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382880606","repostId":2110041062,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":382880152,"gmtCreate":1613415562976,"gmtModify":1634553738629,"author":{"id":"3568188499742215","authorId":"3568188499742215","name":"Derekng","avatar":"https://static.tigerbbs.com/69c847e7e2e81a75b80d5ec94a6f6ae0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382880152","repostId":2110041062,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":382814557,"gmtCreate":1613413423779,"gmtModify":1634553739242,"author":{"id":"3570098181257913","authorId":"3570098181257913","name":"Kles5537","avatar":"https://static.tigerbbs.com/fa48729605e1acd2304bbbabac219bae","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Comment for coins pls&nbsp;","listText":"Comment for coins pls&nbsp;","text":"Comment for coins pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/382814557","repostId":2110041062,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3575485,"gmtCreate":1613415576842,"gmtModify":1635764156680,"authorId":3568188499742215,"author":{"id":3568188499742215,"authorId":3568188499742215,"name":"Derekng","avatar":"https://static.tigerbbs.com/69c847e7e2e81a75b80d5ec94a6f6ae0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":382814557,"type":1,"supId":0,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"}],"langContent":"EN"},{"id":382894116,"gmtCreate":1613403820535,"gmtModify":1634553751343,"author":{"id":"3575534929387028","authorId":"3575534929387028","name":"Nujue","avatar":"https://static.tigerbbs.com/4853f984179f7615aa28fc2a8f1243ad","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Help like pls thank you!","listText":"Help like pls thank you!","text":"Help like pls thank you!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/382894116","repostId":2110041062,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3575573,"gmtCreate":1613426747441,"gmtModify":1635764154194,"authorId":3575256482663287,"author":{"id":3575256482663287,"authorId":3575256482663287,"name":"schipperde","avatar":"https://static.tigerbbs.com/2a4e4121277bf6de1807fa76d4c1d390","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":382894116,"type":1,"supId":0,"prevId":0,"content":"pls help like n comment <u>too</u>","text":"pls help like n comment <u>too</u>","html":"pls help like n comment <u>too</u>"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":314,"commentSize":115,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2110041062"}